Effect of Sertraline on Inflammation in Hemodialysis Patients with Depression: a Randomized Controlled Trial

NAActive, not recruitingINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

October 15, 2024

Primary Completion Date

April 15, 2025

Study Completion Date

April 15, 2025

Conditions
InflamationHemodialysisEnd Stage Renal Disease on Hemodialysis (Diagnosis)
Interventions
DRUG

Sertraline (Oral Antidepressant)

"* 25 mg/day sertraline, titrated up to 100 mg/day based on clinical response and tolerability.~* Administered orally once daily for 12 weeks.~* Used to assess its effects on C-reactive protein (CRP) levels and depressive symptoms in hemodialysis patients."

DRUG

Placebo

"* Identical placebo tablet administered orally once daily for 12 weeks, following the same dosing schedule as the sertraline group.~* Used to compare the effects of sertraline vs. placebo on CRP levels and depression severity in hemodialysis patients."

Trial Locations (1)

66000

Nishtar Hospital, Multan, Multan

All Listed Sponsors
lead

Nishtar Medical University

OTHER

NCT06840379 - Effect of Sertraline on Inflammation in Hemodialysis Patients with Depression: a Randomized Controlled Trial | Biotech Hunter | Biotech Hunter